Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Eli Lilly Says Dulaglutide Meets Primary Endpoint - Quick Facts

Eli Lilly and Co. (LLY: Quote) announced that dulaglutide, its investigational, long-acting glucagon-like peptide 1, or GLP-1, analog being studied as a once-weekly treatment for type 2 diabetes, met its primary endpoint of non-inferiority for mean 24-hour systolic blood pressure after 16 weeks.

According to the company, the results came from a Phase II study that compared two doses of dulaglutide to placebo, using ambulatory blood pressure monitoring to characterize changes in blood pressure and heart rate. Also, the 1.5 mg dulaglutide dose significantly reduced mean 24-hour SBP compared to placebo.

Gwen Krivi, vice president, product development, Lilly Diabetes, said, "We are very encouraged by these clinical trial results, in addition to the rest of the clinical trial data we've seen to date for dulaglutide. Dulaglutide is currently in Phase III clinical trials, where it will continue to be evaluated on its efficacy to lower blood glucose levels, overall safety, weight effects and effects on cardiovascular outcomes. We believe dulaglutide, if approved, can bring significant benefits to people with type 2 diabetes."

Click here to receive FREE breaking news email alerts for Eli Lilly And Co. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Home goods retailer Bed Bath & Beyond Inc. said Tuesday after the markets closed that its second quarter profit fell 10% from last year, as higher costs and expenses more than offset a 4.3% increase in sales. However, the company's quarterly earnings per share came in above analysts' expectations as did its quarterly sales. At the same time, With lawmakers failing to address corporate tax reform before adjourning for the campaign season, the Treasury Department announced Monday that it is taking targeted action to reduce the tax benefits of corporate tax inversions. Technology giant Apple, Inc. announced Monday it has set a new record for first weekend sales of iPhone 6 and 6 Plus, having breached the 10 million mark within just three days of its sales launch on September 19. Sales came from the U.S., Australia, Canada, France, Germany, Hong Kong, Japan, Puerto Rico, Singapore and the UK over the weekend.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.